{"id":"NCT00255047","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Safety and Immune Response of Different Pediatric Combination Vaccines.","officialTitle":"Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2008-07","completion":"2009-02","firstPosted":"2005-11-17","resultsPosted":"2010-11-10","lastUpdate":"2014-02-14"},"enrollment":2167,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Polio","Pertussis"],"interventions":[{"type":"BIOLOGICAL","name":"DAPTACEL®. (DTaP), IPOL®., and ActHIB®.","otherNames":["DAPTACEL®","IPOL®","ActHIB®"]},{"type":"BIOLOGICAL","name":"Pentacel®: DTaP-IPV/Hib combined","otherNames":["Pentacel®"]},{"type":"BIOLOGICAL","name":"DTaP-IPV and ActHIB®","otherNames":["ActHIB®"]},{"type":"BIOLOGICAL","name":"Pentacel®: DTaP-IPV/Hib combined","otherNames":["Pentacel®"]}],"arms":[{"label":"Study Group 1: DAPTACEL®, ActHIB®, and IPOL®","type":"EXPERIMENTAL"},{"label":"Study Group 2: Pentacel®","type":"EXPERIMENTAL"},{"label":"Study Group 3: DTaP-IPV and ActHIB®","type":"EXPERIMENTAL"},{"label":"Study Group 4: Pentacel®","type":"EXPERIMENTAL"}],"summary":"The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3 doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.","primaryOutcome":{"measure":"Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations.","timeFrame":"30 Days post-dose 3 vaccination","effectByArm":[{"arm":"Study Group 1: DAPTACEL®, IPOL®, and ActHIB®","deltaMin":98,"sd":null},{"arm":"Study Group 2: Pentacel®","deltaMin":99,"sd":null},{"arm":"Study Group 3: DTaP-IPV and ActHIB®","deltaMin":99,"sd":null},{"arm":"Study Group 4: Pentacel®","deltaMin":99,"sd":null}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["22475857"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":538},"commonTop":["Irritability","Injection site pain","Anbormal crying","Lethargy","Fever"]}}